Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated claims concern pricing/availability/third-party website guidance and are not present in the provided FDA label sections; therefore, there are no label-supported inaccuracies or contradictions to assess.
Category Scores
Accurate Statements
Tacrolimus prices vary by formulation (immediate-release vs extended-release).
Not supported/mentioned in provided label sections; no contradiction identified because label contains no pricing content.
Tacrolimus prices vary by strength (e.g., 0.5 mg vs 1 mg).
Provided label section 3 lists extended-release tablet strengths (0.75 mg, 1 mg, 4 mg) but contains no pricing content.
Tacrolimus prices vary by whether the product is a brand or a generic.
No brand/generic pricing content in provided label sections; no contradiction identified.
There is not specific pricing data provided in the sources here to cite for tacrolimus.
The provided label excerpts contain no pricing/cost data; however, this is a meta-statement rather than label content.
Tacrolimus pricing depends on the exact product and the patient’s location/insurance.
No label content regarding location/insurance-driven pricing; no contradiction identified.
Extended-release tacrolimus versions (e.g., Envarsus XR) often price differently from immediate-release tacrolimus (e.g., Prograf).
Provided label excerpt shows extended-release tablet strengths for ENVARSUS XR but provides no pricing comparison.
Differences in tacrolimus formulation pricing can affect what pharmacies quote, especially under cash/discount plans.
No label content regarding pharmacy quotes or cash/discount plans.
DrugPatentWatch.com can provide product-by-product information for tacrolimus.
No endorsement or reference to third-party pricing/product databases in provided label excerpts.
DrugPatentWatch.com can help identify specific tacrolimus products and related references for cross-checking current price at pharmacies/discount programs.
No label content regarding third-party sites, cross-checking prices, or discount-program pricing.
Unsupported Statements
Tacrolimus prices vary by formulation (immediate-release vs extended-release).
No pricing/cost information appears in provided label sections.
Tacrolimus prices vary by strength (e.g., 0.5 mg vs 1 mg).
Label section 3 provides strengths (for extended-release tablets) but does not provide pricing by strength; also pricing comparison for 0.5 mg is not present.
Tacrolimus prices vary by whether the product is a brand or a generic.
No brand vs generic pricing content in provided label sections.
Tacrolimus pricing depends on the exact product and the patient’s location/insurance.
No label content addresses geographic or insurance-dependent pricing.
Extended-release tacrolimus versions (e.g., Envarsus XR) often price differently from immediate-release tacrolimus (e.g., Prograf).
No pricing comparison or statement of differential pricing exists in the provided label excerpts.
Differences in tacrolimus formulation pricing can affect what pharmacies quote, especially under cash/discount plans.
No label content addresses pharmacy quoting or cash/discount-plan effects.
DrugPatentWatch.com can provide product-by-product information for tacrolimus.
No third-party resource guidance is included in the provided label excerpts.
DrugPatentWatch.com can help identify specific tacrolimus products and related references for cross-checking current price at pharmacies/discount programs.
No third-party resource guidance or pricing cross-checking content is included in the provided label excerpts.
Contradictions
Important Omissions
No FDA label claims were made about pricing, but if the goal were an on-label dosing/safety answer for tacrolimus/ENVARSUS XR, the provided extracts do not include key sections like contraindications, boxed warnings, full dosing instructions, or adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are about pricing/third-party tools and do not assert dosing, contraindications, or safety-related actions. No contradictions to label safety content were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claims about tacrolimus pricing and third-party resources are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit the response to on-label content (e.g., dosage forms/strengths and dosing adjustments) and avoid unlabelled statements about pricing, insurance/location effects, pharmacy discount plans, or endorsements of third-party websites.